Perfuse Therapeutics develops targeted therapies using specialized drug delivery systems to treat eye diseases that cause vision loss. The company aims to enhance patient outcomes by providing precise treatment options tailored to specific ocular conditions.
Funding
$11M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Glaucoma and diabetic retinopathy are leading causes of blindness, affecting millions worldwide despite existing treatments. These diseases are often driven by retinal ischemia, or insufficient blood flow to the retina, which damages and eventually kills retinal cells. Current standard of care treatments do not adequately address the underlying pathology of reduced ocular blood flow in these ischemic ocular diseases.
Solution
Perfuse Therapeutics is developing a first-in-class endothelin antagonist, PER-001, delivered via a sustained-release intravitreal implant, to improve ocular blood flow and prevent retinal cell death. By blocking pathological endothelin signaling, which constricts blood vessels and reduces blood flow, PER-001 aims to address the underlying pathology in ocular diseases driven by ischemia. The sustained-release implant is designed to release the drug over six months following a single intravitreal administration, providing long-lasting therapeutic benefits. This approach has the potential to significantly improve outcomes for patients suffering from glaucoma and diabetic retinopathy.
Target Audience
The primary target audience includes patients with glaucoma and diabetic retinopathy, as well as ophthalmologists and retina specialists seeking novel therapies to improve ocular blood flow and prevent vision loss.
Features
- PER-001: A first-in-class small molecule endothelin antagonist
- Sustained-release intravitreal implant designed for 6-month drug delivery
- Targets endothelin signaling to improve retinal blood flow
- Addresses ischemia-driven pathology in glaucoma and diabetic retinopathy